Skip to content

Use of calcium carbonate supplementation to prevent Pre-eclampsia in pregnant women high risk: randomized clinical trial

Use of calcium carbonate supplementation to prevent Pre-eclampsia in pregnant women high risk: randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7hqhj3y
Enrollment
Unknown
Registered
2023-11-16
Start date
2024-01-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unspecified pre-eclampsia

Interventions

A triple-blind Randomized Controlled Clinical Trial (RCT) will be carried out. Pregnant women will be centrally allocated to one of three groups: experimental group I, experimental group II and contro

Sponsors

Centro de Ciências Biológicas e da Saúde - Universidade Federal de Sergipe
Lead Sponsor
Universidade Federal de Sergipe
Collaborator

Eligibility

Sex/Gender
Female
Age
15 Years to No maximum

Inclusion criteria

Inclusion criteria: Pregnant women who are up to the 20th week of pregnancy at the first stage of the approach; minumium age of 15 years; who present one or more of the risk factors: history of pre-eclampsia, multiple pregnancy, chronic hypertension, type 1 or 2 diabetes, autoimmune disorder) will be included in the study. , kidney disease, nulliparity, body mass index >30 kg/m2, family history of preeclampsia (first-degree relative), sociodemographic characteristics (African American, low socioeconomic status), age >35 years, history factors (pre-low birth weight or small birth for gestational age, previous adverse pregnancy outcome, interval >10 years since previous pregnancy, term birth without previous complications) for the occurrence of pre-eclampsia; and/or low intake of calcium

Exclusion criteria

Exclusion criteria: Pregnant women with known placental abnormalities; current pregnancy as a result of in vitro fertilization; regular use of platelet-active drugs; known fetal abnormalities; uterine bleeding documented within one week of screening; uterine malformations; pregnant women with chronic systemic hypertension; sickle cell anemia; those under 15 years of age

Design outcomes

Primary

MeasureTime frame
A sample of at least 120 patients in each group is expected to provide 80% power to detect a 50% reduction in the incidence of PE and the estimate that 30% of high-risk pregnant women develop pre-eclampsia, using a two-sided t-test with an a level of 0.05.

Secondary

MeasureTime frame
No secondary outcomes are expected

Countries

Brazil

Contacts

Public ContactCinara Rejane Oliveira

Universidade Federal de Sergipe

cinararvo@academico.ufs.br+55(71)99216-2300

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 6, 2026